RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RxSight Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immuneering (IMRX – Research Report) and RxSight (RXST – Research...

Current Quarter	$-0.3	Next Quarter	$-0.34
Current Year	$-1.35	Next Year	$-1.15
QoQ Growth	-13.3%	YoY Growth	+14.8%
3Y EPS CAGR	+41.6%	Target Price	$10.06
Consensus	Buy	Upside	+48.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RXST	$6.76	0.00%	430.27K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RXST	$6.76	0%	430.27K
3
4
5
6

RXST

RXST

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get RxSight Inc. Data in Excel

Get RxSight Inc. Data in Excel